Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,443 across all filing types
Latest filing 2018-07-11 Capital/Financing Update
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Appendix 3B and 708A Notice 14 pages 1.5MB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new shares and options, including the number of securities issued, terms, issue price, purpose, and quotation details. It references ASX rules and compliance, and includes sections on security holder approvals, underwriting, and quotation agreements. This type of document is a formal announcement related to capital raising activities, specifically the issuance of new securities and their quotation on the exchange. It is not a full financial report, earnings release, or management discussion, but rather a regulatory announcement about capital changes. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive capital raising announcement.
2018-07-11 English
Change of Director's Interest Notice - PH 2 pages 39.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of shares and options held before and after the change, nature of the change, and value consideration. The document is a formal notification of a director's personal share transactions to the stock exchange. It does not contain financial statements, management discussion, or other report content. The document length is 4137 characters, which is consistent with a notice rather than a full report. This matches the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades).
2018-07-11 English
Change of Director's Interest Notice - LC 2 pages 39.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of shares and options held before and after the change, nature of the change, and value consideration. The document is a formal notification of a director's personal share transactions. It does not contain financial statements, management discussion, or other report content. The document length is 4158 characters, which is consistent with a detailed insider trading notification. According to the filing definitions, reports of personal share transactions by company directors and executives (insider trades) are classified as Director's Dealing (DIRS). Therefore, this document is best classified as DIRS.
2018-07-11 English
Change of Director's Interest Notice - CW 2 pages 39.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including shares and options acquired or disposed, and the nature of the change (e.g., participation in entitlement offer). The document is a formal notification of insider share transactions by a company director. It does not contain financial statements, earnings data, or management discussion. The content matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 4252 characters, which is consistent with a detailed insider trading notice rather than a full financial report or announcement. Therefore, the correct classification is DIRS (Director's Dealing).
2018-07-11 English
Becoming a substantial holder 4 pages 109.0KB
Regulatory Filings Classification · 90% confidence The document text is extremely short (884 characters) and mostly consists of unintelligible or corrupted content with no clear financial data, report titles, regulatory references, or fiscal period information. There are no indications of a full report, announcement, or certification. Given the lack of substantive content and the presence of what appears to be a fragment or placeholder text, the best fit classification is Regulatory Filings (RNS), which serves as a fallback category for miscellaneous filings that do not fit other specific categories.
2018-07-09 English
General Meeting Presentation 10 pages 1.0MB
Investor Presentation Classification · 95% confidence The document is a presentation given by the Managing Director & CEO at a July 2018 General Meeting. It contains detailed information about the company's strategy, management team, acquisition, and pipeline related to B-cell cancer immunotherapy. The content is structured as a presentation with slides, forward-looking statements, and strategic updates. There are no financial statements or detailed financial data typical of annual or interim reports. It is not an earnings release or a regulatory filing. The document is clearly a detailed presentation aimed at investors and stakeholders, focusing on company strategy, pipeline, and management credentials. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (7778 characters) and content support this classification with high confidence.
2018-07-08 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.